Trial Profile
A Phase I/II Study Evaluating the Effect of IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) on Minimal Residual Disease (MRD) as determined by Second Look Laparoscopy when Administered in Combination with Bevacizumab and Neoadjuvant Chemotherapy in Subjects Newly Diagnosed with Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Apr 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; IMNN 001 (Primary) ; Antineoplastics; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 28 Mar 2024 According to an Imunon media release, the company enrolled four patients in a Phase 1/2 clinical trial evaluating IMNN-001 in combination with bevacizumab in patients with advanced ovarian cancer at the University of Texas MD Anderson Cancer Center,
- 27 Feb 2024 According to an Imunon media release, company announced that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON's IMNN-001 in combination with bevacizumab in patients with advanced ovarian cancer.
- 18 Oct 2023 According to an Imunon media release, Initial SLL data are expected within one year following the completion of enrollment and final PFS data are expected approximately three years following the completion of enrollment.